Drugs / ZYD1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01972893 | Feb 2011 → Mar 2012 | type 2 diabetes mellitus | Zydus Lifesciences Limited | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2009-06-04 | Zydus Lifesciences Limited | Regulatory Zydus files IND application with the DCGI for ZYD1 - a novel candidate to treat Diabetes and Obesity zyduslife.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2009-06-04 | Zydus Lifesciences Limited | Zydus files IND application with the DCGI for ZYD1 - a novel candidate to treat Diabetes and Obesity zyduslife.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZYD1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01972893 ↗ |
| Action | Activate | “ZYD1 is a novel GLP-1 receptor agonist.” NCT01972893 ↗ |
| Route | Subcutaneous | “Following Subcutaneous Administration” NCT01972893 ↗ |